Creative Medical Technology Holdings (CELZ) Cash & Equivalents (2010 - 2026)

Creative Medical Technology Holdings (CELZ) has reported Cash & Equivalents for 17 consecutive years, with $5.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 25.7% year-over-year to $5.7 million; the TTM figure through Mar 2026 stood at $5.7 million (down 25.7% YoY), while the FY2025 annual figure was $7.2 million, up 21.34% from the prior year.
• Cash & Equivalents fell to $5.7 million in Q1 2026 per CELZ's latest filing, from $7.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $22.9 million in Q2 2022 and bottomed at $3.5 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $8.2 million across 5 years, with a median of $7.2 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 14317.02% — and 2023, when it sank 82.55%.
• Creative Medical Technology Holdings' Cash & Equivalents stood at $8.3 million in 2022, then tumbled by 58.33% to $3.5 million in 2023, then jumped by 71.35% to $5.9 million in 2024, then advanced by 21.34% to $7.2 million in 2025, then declined by 20.6% to $5.7 million in 2026.
• Business Quant data shows CELZ's Cash & Equivalents at $5.7 million in Q1 2026, $7.2 million in Q4 2025, and $5.4 million in Q3 2025.